Study detail
RecruitingPhase 1
Long-Term Follow-Up (LTFU) of Participants Treated With ADP Adoptive Cell Therapies
USWM CT, LLC
Summary
This trial will evaluate long term safety of participants who have received AdaptImmune (ADP) adoptive cell therapy for up to 15 years following last adoptive cell therapy infusion.
Description
Participants who received a ADP adoptive cell therapy will be enrolled in this non-therapeutic, multi-center, long term follow-up (LTFU) study and will be followed for up to 15 years post-infusion of lentiviral vector-based adoptive cell therapy. Participants will be monitored for safety following last adoptive cell therapy infusion.
Eligibility
- Age range
- Not specified
- Sex
- All
- Healthy volunteers
- No